# Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy

> **NCT07371247** · EARLY_PHASE1 · ENROLLING_BY_INVITATION · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 65 (estimated)

## Conditions studied

- Esophageal Cancer
- MRD
- ctDNA

## Interventions

- **DRUG:** Step-up therapy
- **DRUG:** Standard treatment Routine treatment

## Key facts

- **NCT ID:** NCT07371247
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-12-20
- **Primary completion:** 2027-10-31
- **Final completion:** 2027-11-30
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2026-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07371247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07371247, "Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Study on Safety and Efficacy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07371247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*